Skip to main content
SpringerLink
Log in

Poor Mobilisation After Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple Myeloma

  • Correspondence
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jandial A, Mishra K, Lad D, Prakash G, Khadwal A, Malhotra P (2018) Real world experience with "generic" pomalidomide in relapsed refractory multiple myeloma. Leuk Lymphoma 15:1–3. https://doi.org/10.1080/10428194.2018.1508675

    Article  CAS  Google Scholar 

  2. Sandal R, Jandial A, Mishra K, Lad D, Prakash G, Khadwal A (2018) Real world experience of generic carfilzomib for relapsed refractory multiple myeloma (RRMM). Indian J Hematol Blood Transfus 34(Suppl 1):372

    Google Scholar 

  3. Jandial A, Mishra K, Prakash G, Malhotra P (2018) Sudden cardiac arrest after daratumumab infusion. Indian J Med Paediatr Oncol. https://doi.org/10.1080/10428194.2018.1508675

    Article  Google Scholar 

  4. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S et al (2018) Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 378(6):518–528

    Article  CAS  PubMed  Google Scholar 

  5. Jakubowiak Andrzej J, Chari Ajai, Lonial Sagar, Weiss Brendan M, Comenzo Raymond L, Kaida Wu et al (2017) Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study. J Clin Oncol 35:8000

    Article  Google Scholar 

  6. Voorhees PM, Rodriguez C, Reeves B, Nathwani N, Costa LJ, Lutska Y et al (2018) Efficacy and updated safety analysis of a safety run-in cohort from griffin, a phase 2 randomized study of daratumumab (Dara), bortezomib (V), lenalidomide (R), and dexamethasone (D; Dara‐Vrd) vs. Vrd in patients (Pts) with newly diagnosed (ND) multiple myeloma (MM) eligible for high‐dose therapy (HDT) and autologous stem cell transplantation (ASCT). Blood 132(Suppl 1):151.

    Google Scholar 

  7. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113(23):5720–5726

    CAS  PubMed  Google Scholar 

  8. Wallis WD, Qazilbash MH (2017) Peripheral blood stem cell mobilization in multiple myeloma: growth factors or chemotherapy? World J Transplant 7(5):250–259

    Article  PubMed  PubMed Central  Google Scholar 

  9. Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J et al (2014) Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 20(3):295–308

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Post-Graduate Institute of Medical Education and Research, Chandigarh, 160012, India

    Kundan Mishra, Aditya Jandial, Rajeev Sandal, Deepesh Lad, Gaurav Prakash, Alka Khadwal & Pankaj Malhotra

Authors
  1. Kundan Mishra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aditya Jandial
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rajeev Sandal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Deepesh Lad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gaurav Prakash
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alka Khadwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pankaj Malhotra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pankaj Malhotra.

Ethics declarations

Conflict of interest

There is no conflict of interest between the authors.

Informed Consent

Informed signed written consent was taken from the patient involved.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Human and Animals Rights

No animals were involved in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mishra, K., Jandial, A., Sandal, R. et al. Poor Mobilisation After Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple Myeloma. Indian J Hematol Blood Transfus 35, 584–586 (2019). https://doi.org/10.1007/s12288-019-01135-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-019-01135-4

Search

Navigation